Cardiff Oncology, Inc. CRDF R2K
Healthcare · Biotechnology · United States
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
READ MORE ›$1.90
-44.28% 1Y
Market & Price
Market Cap
$129.90M
Current Price
$1.90
High / Low (52W)
$4.45 / $1.48
Beta
1.36
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.51
Price to Book
3.74
P/S
247.43
EV/EBITDA
-1.79
Dividend Yield
-
Profitability & Returns
ROCE
-107.63%
ROE
-84.79%
ROA
-44.25%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.18
EPS (TTM)
$-0.67
Balance Sheet & Liquidity
Debt/Equity
1.86
Quick Ratio
3.20
Current Ratio
3.27
Debt
$646.00K
Total Assets
$61.88M
Current Assets
$60.13M
Working Capital
$43.73M
Ownership
Promoter Holding
5.91%
Chg in Prom Hold
-
FII / Inst Holding
32.86%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$84.49M
Total Revenue (TTM)
$525.00K
EBITDA
$-47.07M
Free Cash Flow
$-20.02M
Operating Cash Flow
$-37.42M
Shares Outstanding
68.37M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
15.39%
Profit 5Y
-6.16%
Revenue (YoY)
-62.40%
Earnings (YoY)
-
PROS
- Compounding revenue at 15.4% over 5 years.
CONS
- Earnings shrank at -6.2% CAGR over 5 years.
- Trading 57.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRDF Cardiff Oncology, Inc. R2K | 1.90 | - | $129.90M | - | -107.63% | -84.79% | 15.39% | -6.16% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.02K | 36.85K | 51.69K | 68.00K | 43.00K | 136.00K | 72.00K | 68.00K | 86.00K | 74.00K | 91.00K | 93.00K | 83.00K | 108.00K | 141.00K | 205.00K | 163.00K | - | - | 109.00K | 121.00K | 120.00K | 243.00K | 41.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.49M | 14.90M | 12.09M | 8.07M | 12.89M |
| Operating Income | - | -4.85M | -6.63M | -6.41M | - | -10.46M | -9.98M | -9.92M | - | -10.13M | -5.89M | -5.80M | - | -4.66M | -4.44M | -3.86M | -3.96M | -4.22M | -4.21M | -4.12M | -4.10M | -4.36M | -5.44M | -6.89M | -7.00M | -11.07M | -10.44M | -8.99M | -12.05M | -12.21M | -10.82M | -10.93M | -12.54M | - | - | -14.38M | -14.78M | -11.97M | -7.83M | -12.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.15M | -14.78M | -11.48M | -7.60M | -12.63M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.43M | -13.94M | -11.26M | -7.22M | -12.35M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | -7.17M | -10.18M | -2.74M | - | -10.26M | -10.20M | -10.19M | - | -10.00M | -8.05M | -4.29M | - | -4.79M | -3.75M | -3.77M | -3.90M | -4.13M | -4.14M | -4.09M | -4.12M | -4.50M | -5.18M | -6.76M | -6.91M | -10.99M | -10.44M | -8.57M | -11.22M | -11.15M | -9.73M | -10.01M | -11.78M | - | - | -13.43M | -13.94M | -11.26M | -7.22M | -12.35M |
| Diluted EPS | -0.25 | -0.33 | -0.41 | -0.23 | -0.26 | -0.36 | -0.34 | -0.34 | -0.34 | -0.32 | -3.12 | -1.41 | -0.06 | -6.23 | -5.27 | -1.10 | -1.02 | -0.79 | -0.71 | - | -0.51 | -0.19 | -0.14 | -0.17 | -0.17 | -0.25 | -0.24 | -0.20 | -0.25 | -0.25 | -0.22 | -0.22 | -0.26 | -0.25 | - | -0.20 | -0.21 | -0.17 | - | -0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2001 | Jan 2002 | Jan 2003 | Jan 2004 | Jan 2005 | Jan 2006 | Jan 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 366.00K | - | 386.00K | 488.00K | 683.00K | 593.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.29M | 45.90M | 49.33M | 49.55M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | -2.98M | -4.85M | -10.69M | -14.95M | -25.27M | -40.15M | -25.60M | -17.05M | -16.68M | -19.09M | - | -39.90M | -45.41M | -48.65M | -48.96M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.67M | -45.01M | -47.71M | -48.06M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -38.70M | -41.44M | -45.43M | -45.85M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -267.60K | -524.22K | -481.61K | -383.02K | -5.37M | -7.84M | -7.13M | -4.68M | -5.17M | -2.48M | -5.45M | -2.24M | -11.57M | -11.81M | -14.33M | -27.47M | -39.20M | -24.91M | -16.46M | -16.41M | -19.31M | - | -38.70M | -41.44M | -45.43M | -45.85M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.89 | -0.70 | -0.88 | -1.21 | -1.37 | -51.76 | -8.26 | - | -1.08 | - | -0.89 | -0.93 | -0.95 | -0.69 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.24M | 17.40M | 27.10M | - | - | - |
Compounded Sales Growth
| 5 Years: | 15.39% |
| 1 Year: | -62.40% |
Compounded Profit Growth
| 5 Years: | -6.16% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -44.28% |
| 6 Months: | -9.95% |
| 3 Months: | -2.06% |
| 1 Month: | +17.28% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2000 | Jan 2001 | Jan 2002 | Jan 2003 | Jan 2004 | Jan 2005 | Jan 2006 | Jan 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | 1.04M | 11.67M | 27.16M | 28.90M | 71.45M | 43.95M | 12.28M | 14.17M | 13.09M | 134.73M | - | 116.19M | 81.64M | 97.19M | 61.88M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.28M | 77.41M | 95.05M | 60.13M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | 58.70K | 700.37K | 10.82M | 25.84M | 27.29M | 67.49M | 13.92M | 8.23M | 11.45M | 10.20M | 130.98M | - | 16.35M | 21.66M | 51.47M | 17.47M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 771.00K | 288.00K | 773.00K | 182.00K |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 5.27M | 9.50M | 6.76M | 20.55M | 22.74M | 24.18M | 5.78M | 4.09M | 5.78M | 6.57M | - | 9.85M | 11.90M | 14.24M | 16.50M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | 1.43M | 730.37K | 2.01M | 4.49M | 8.20M | 7.80M | 3.95M | 2.92M | 4.78M | 6.12M | - | 7.81M | 10.44M | 13.43M | 16.39M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.71M | 2.15M | 1.52M | 832.00K |
| Total Equity | 27.24K | -240.36K | -719.39K | -1.20M | -1.58M | 3.19M | 3.48M | 1.13M | -1.65M | -4.05M | -3.79M | -5.00M | -4.23M | 2.17M | 20.39M | 8.35M | 48.70M | 19.77M | 6.51M | 10.08M | 7.31M | 128.16M | - | 106.34M | 69.74M | 82.95M | 45.39M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.68M | 44.68M | 66.52M | 68.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | -13.20M | -13.27M | -16.32M | - | -33.82M | -30.89M | -37.69M | -37.92M |
| Investing Cash Flow | - | - | - | - | - | - | - | 22.84K | -67.62K | -211.00K | - | 38.15M | 36.20M | 13.73M | 1.34M |
| Financing Cash Flow | - | - | - | - | - | - | - | 16.40M | 12.08M | 137.31M | - | 75.00K | 0 | 53.78M | 2.58M |
| Capital Expenditure | -1.53K | -274.08K | -649.78K | -363.29K | -2.24M | -823.48K | -101.10K | -5.10K | -67.62K | -211.00K | - | -1.01M | -582.00K | -80.00K | -44.00K |
| Free Cash Flow | - | - | - | - | - | - | - | -13.20M | -13.34M | -16.53M | - | -34.83M | -31.47M | -37.77M | -37.97M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | 4.40M | 5.31M | 29.82M | -34.00M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2001 | Jan 2002 | Jan 2003 | Jan 2004 | Jan 2005 | Jan 2006 | Jan 2007 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5,214.8% | - | -10,337.3% | -9,305.7% | -7,123.1% | -8,256.3% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5,275.1% | - | -10,026.9% | -8,492.0% | -6,651.7% | -7,732.0% |
| ROE % | 111.3% | 72.9% | 40.3% | 24.3% | -168.3% | -225.4% | -631.5% | 284.6% | 127.6% | 65.6% | 109.1% | 52.9% | -533.2% | -57.9% | -171.6% | -56.4% | -198.3% | -382.8% | -163.2% | -224.5% | -15.1% | - | -36.4% | -59.4% | -54.8% | -101.0% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | 762.1% | -44.3% | -42.5% | -61.2% | -40.0% | -111.0% | -306.9% | -151.6% | -200.8% | -14.8% | - | -36.8% | -63.8% | -58.1% | -107.6% |
Shareholding Pattern
Insiders
5.91%
Institutions
32.86%
Public Float
34.93%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 5.82% | 3.98M | $7.56M |
| 2 | Vanguard Capital Management LLC | 4.18% | 2.86M | $5.43M |
| 3 | Laurion Capital Management, LP | 3.87% | 2.65M | $5.03M |
| 4 | Pfizer Inc | 3.53% | 2.41M | $4.58M |
| 5 | Acorn Capital Advisors, LLC | 2.58% | 1.76M | $3.35M |
| 6 | Geode Capital Management, LLC | 2.34% | 1.60M | $3.04M |
| 7 | Franklin Resources, Inc. | 1.76% | 1.21M | $2.29M |
| 8 | State Street Corporation | 1.74% | 1.19M | $2.26M |
| 9 | BLAIR WILLIAM & CO/IL | 1.35% | 922.41K | $1.75M |
| 10 | FLPutnam Investment Management Company | 0.87% | 595.13K | $1.13M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRDF
No recent headlines available.